The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs

Research output: Contribution to journal › Editorial

Access to Document

@article{2d812cd05b454a038439d2d8b40c2c0c,

title = "The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs",

author = "Michot, \{J. M.\} and C. Bigenwald",

year = "2025",

month = jul,

doi = "10.1016/j.annonc.2025.04.008",

language = "English",

volume = "36",

pages = "711",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs

AU - Michot, J. M.

AU - Bigenwald, C.

PY - 2025/7

Y1 - 2025/7

UR - https://www.scopus.com/pages/publications/105006739287

U2 - 10.1016/j.annonc.2025.04.008

DO - 10.1016/j.annonc.2025.04.008

M3 - Editorial

C2 - 40288677

AN - SCOPUS:105006739287

SN - 0923-7534

VL - 36

SP - 711

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -